Structure‐guided design of G‐Protein‐Coupled receptor polypharmacology

dc.contributor.affiliationUniversidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS)
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica
dc.contributor.authorKampen, Stefanie
dc.contributor.authorDuy Vo, Duc
dc.contributor.authorZhang, Xiaoqun
dc.contributor.authorPanel, Nicolas
dc.contributor.authorYang, Yunting
dc.contributor.authorJaiteh, Mariama
dc.contributor.authorMatricon, Pierre
dc.contributor.authorSvenningsson, Per
dc.contributor.authorBrea Floriani, José Manuel
dc.contributor.authorLoza García, María Isabel
dc.contributor.authorKihlberg, Jan
dc.contributor.authorCarlsson, Jens
dc.date.accessioned2026-01-13T08:11:35Z
dc.date.available2026-01-13T08:11:35Z
dc.date.issued2021-04-27
dc.description.abstractMany diseases are polygenic and can only be treated efficiently with drugs that modulate multiple targets. However, rational design of compounds with multi-target profiles is rarely pursued because it is considered too difficult, in particular if the drug must enter the central nervous system. Here, a structure-based strategy to identify dual-target ligands of G-protein-coupled receptors is presented. We use this approach to design compounds that both antagonize the A2A adenosine receptor and activate the D2 dopamine receptor, which have excellent potential as antiparkinson drugs. Atomic resolution models of the receptors guided generation of a chemical library with compounds designed to occupy orthosteric and secondary binding pockets in both targets. Structure-based virtual screens identified ten compounds, of which three had affinity for both targets. One of these scaffolds was optimized to nanomolar dual-target activity and showed the predicted pharmacodynamic effect in a rat model of Parkinsonism
dc.description.peerreviewedSI
dc.description.sponsorshipSwedish Research Council (2017-4676), the Swedish brain foundation (FO2019-0299), Xunta de Galicia (ED431C 2018/21), the Spanish Ministry of Science and Innovation (SAF2017-85225-C3-1-R), and the European Regional Development Fund (ERDF)
dc.identifier.citationS. Kampen, D. Duy Vo, X. Zhang, N. Panel, Y. Yang, M. Jaiteh, P. Matricon, P. Svenningsson, J. Brea, M. I. Loza, J. Kihlberg, J. Carlsson, Angew. Chem. Int. Ed. 2021, 60, 18022
dc.identifier.doi10.1002/anie.202101478
dc.identifier.essn1521-3773
dc.identifier.urihttps://hdl.handle.net/10347/45058
dc.issue.number33
dc.journal.titleAngewandte Chemie International Edition
dc.language.isoeng
dc.page.final18030
dc.page.initial18022
dc.publisherWiley
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/715052
dc.relation.publisherversionhttps://doi.org/10.1002/anie.202101478
dc.rights© 2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectDrug design
dc.subjectParkinson’s disease
dc.subjectPolypharmacology
dc.subjectReceptors
dc.subjectVirtual screening
dc.titleStructure‐guided design of G‐Protein‐Coupled receptor polypharmacology
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number60
dspace.entity.typePublication
relation.isAuthorOfPublication67b19be7-64a8-45c8-a6e4-ed48a4410ef8
relation.isAuthorOfPublication7765cb9b-b630-44dc-9477-dd266a62bb3c
relation.isAuthorOfPublication.latestForDiscovery67b19be7-64a8-45c8-a6e4-ed48a4410ef8

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021_AngChem_Kampen_Structure.pdf
Size:
1.59 MB
Format:
Adobe Portable Document Format